Results 201 to 210 of about 3,808,290 (359)

RENAL‐CHIP: Rejection Evaluation via Non‐Invasive Analysis of Circulating Podocytes With Herringbone‐Chip Isolation Platform

Advanced Science, EarlyView.
RENAL‐CHIP converts 1 mL of peripheral blood into a biopsy‐equivalent readout of renal‐allograft fate. By magnetic capture and release of donor‐derived circulating podocytes through a herringbone microfluidic chip, 84% capture, 96% release and single‐cell RNA evidence of rejection‐specific immunity are achieved.
Juan Song, Yilong Liu, Zeyuan Zheng, Ming Zhu, Yuning Zou, Pei Liu, Yue Zheng, Xiyuan Yu, Jianzhong Zheng, Chen Shao, Huimin Zhang, Chaoyong Yang   +11 more
wiley   +1 more source

Thrombotic thrombocytopenic purpura: a Trojan horse of acute leukemia?: a case report. [PDF]

J Med Case Rep
Nassani BM, Eid H, Mourad D, Riachy M, Maalouly G.   +4 more
europepmc   +1 more source

IGFBP5 Restores Endometrial Receptivity and Rescues Implantation Failure in Polycystic Ovary Syndrome

Advanced Science, EarlyView.
Impaired endometrial receptivity contributes to the poor pregnancy outcomes in women with PCOS. The authors found that decreased endometrial IL‐22 levels and disrupted STAT3‐IGFBP5 signaling pathway contributed to impaired endometrial receptivity. Supplementation with IL‐22 or IGFBP5 exerts a protective effect on implantation failure in PCOS‐like mice,
Baoying Liao, Chuyu Yun, Hongying Shan, Yuqian Wang, Xiunan Chen, Weisi Lian, Tianliu Peng, Min Zhao, Xunsi Qin, Kailun Hu, Ping Zhou, Yue Wang, Yanli Pang, Rong Li   +13 more
wiley   +1 more source

Rapid epigenomic classification of acute leukemia. [PDF]

Nat Genet
Steinicke TL, Benfatto S, Capilla-Guerra MR, Monteleone AB, Young JH, Shankar S, Michaels PD, Tsai HK, Good JD, Kreso A, van Galen P, Schliemann C, Chen EC, Griffin GK, Hovestadt V.   +14 more
europepmc   +1 more source

AML‐Targeted Metal‐Polyphenol Nanoplatform Induces Ferroptosis‐ICD Cascade for Antitumor Immunity Boosting

Advanced Science, EarlyView.
Schematic illustration of the synthesis protocol for Fe‐SH@Fn, an AML‐targeted nanoplatform engineered to co‐deliver shikonin (SH) and Fe3+, synergistically boosting antitumor immunity via ferroptosis induction and immunogenic cell death (ICD). ABSTRACT Acute myeloid leukemia (AML) remains a therapeutic challenge due to its low immunogenicity and ...
Shangqin Yang, Jingxuan Wang, Kerong Tu, Xiaobing Huang, Liangliang Lv, Mingjie Peng, Qiqi Xu, Hongmei Liu, Qiang Sun, Lulu Cai   +9 more
wiley   +1 more source

Major Adverse Cardiovascular Events and Cardiac Dysfunction in Patients With Acute Leukemia: A Prospective Study. [PDF]

JACC CardioOncol
Kang Y, Lefebvre B, Smith A, Koropeckyj-Cox D, Brahmbhatt P, Ky B, Carver J, McCurdy S, Luger S, Scherrer-Crosbie M.   +9 more
europepmc   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Case Report: The diagnostic and therapeutic crossroads: when myelofibrosis transforms into mixed phenotype acute leukemia. [PDF]

Front Oncol
Liu Y, Zhang J, Du X, Liao L.
europepmc   +1 more source

NUDT21 Drives T‐Cell Acute Lymphoblastic Leukemia Through Dual Regulation of Alternative Polyadenylation and Transcriptional Activation

Advanced Science, EarlyView.
In summary, our study defines a coordinated oncogenic model in which NUDT21 integrates alternative polyadenylation–dependent UBE2D3 stabilization and transcriptional activation to sustain MYC‐driven T‐ALL cell survival, thereby establishing NUDT21 as a central regulatory node and a promising therapeutic target.
Conglian Qiu, Jianwei Wang, Zhiheng Li, Qi Ji, Hui Zhang, Qinyi Zhang, Senlin Zhang, Juanjuan Yu, Yanfang Tao, Yijun Wu, Chunxia Shi, Zong Zai, Zimu Zhang, Yizhen Li, Zhenjiang Bai, Shaoyan Hu, Jian Pan, Yang Yang, Shuiyan Wu   +18 more
wiley   +1 more source

Revuforj (revumenib): a novel menin inhibitor for relapsed or refractory acute leukemia. [PDF]

Ann Med Surg (Lond)
Imtiaz A, Nazeer A, Haider E, Imran SB.
europepmc   +1 more source